Parsing the subsets: When small studies create confusion

Catheterization and Cardiovascular Interventions

Volumn 72, Issue 1, 2008, Pages 23-24

  Blankenship, James C ^a,b  

^a GEISINGER MEDICAL CENTER   (United States)

^b Geisinger Medical center ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RAPAMYCIN;

BARE METAL STENT; DRUG ELUTING STENT; FOLLOW UP; HEART DEATH; HUMAN; IN-STENT RESTENOSIS; NOTE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SAFETY; SAPHENOUS VEIN GRAFT; STENT;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; DRUG-ELUTING STENTS; GRAFT OCCLUSION, VASCULAR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYOCARDIAL ISCHEMIA; RESEARCH DESIGN; SAPHENOUS VEIN; TREATMENT OUTCOME; TUBULIN MODULATORS;

EID: 47549119521     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.21648     Document Type: Note

References (8)

1. Vermeersch P, Agostoni P, Verheye S, Van den Heuval P, Convens C, Van den Branden F, Van Langenhove G. Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts. J Am Coll Cardiol 2007;50: 261-267.
2. Gioia G, Benassi A, Mohendra R, et al. Lack of clinical long-term benefit with the use of a drug eluting stent compared to use of a bare metal stent in saphenous vein grafts. Catheter Cardiovasc Interv 2008;72:13-20.
3. Lee MS, Shah AP, Aragon J, Jamali A, Dohad S, Kar S, Makkar RR. Drug-eluting stenting is superior to bare metal stenting in saphenous vein grafts. Cathet Cardiovasc Interv 2005;66: 507-511.
4. Chu WW, Rha SW, Kuchalakanti PK, Cheneau E, Torguson R, Pinnow E, Alexieva-Fournadjiev J, Pichard AD, Satler LF, Kent KM, Lindsay J, Waksman R. Efficacy of sirolimus-eluting stents compared with bare metal stents for saphenous vein graft intervention. Am J Cardiol 2006;97:34-37.
5. Minutello RM, Bhagan S, Sharma A, Slotwiner AJ, Feldman DN, Cuomo LJ, Wong SC. Long-term clinical benefit of sirolimus-eluting stents compared to bare metal stents in the treatment of saphenous vein graft disease. J Interv Cardiol 2007;20:458-465.
6. Vignali L, Saia F, Manari A, Snatarelli A, Rubboli A, Varani E, Piovaccari G, Menozzi A, Percoco G, Benassi A, Rusticali G, Marzaroli P, Guastaroba P, Grilli R, Maresta A, Marzocchi A. Long-term outcomes with drug-eluting stents versus bare metal stents in the treatment of saphenous vein graft disease (results from the Registro Regionale AngiopLastiche Emilia-Romagna Registry). Am J Cardiol 2008;101:947-992.
7. Baldwin DE, Trost JC, Abbott D, Vlachos H, Glaser R, Wilensky RL, Slater JN, Beohar N, Williams DO. A comparison of drug-eluting and bare-metal stents for saphenous vein graft lesions: A report from the National Heart, Lung, and Blood Institute Dynamic Registry. Cathet Cardiovasc Interv 2008;71:E26 (abstract).
8. Hodgson J McB, Lincoff AM, Klein L, Walpole H, Bottner R, Weinger BH, Leon MB, Feldman T, Babb J, Dehmer GJ. Late stent thrombosis: Considerations and practical advice for the use of drug-eluting stents: A report from the Society for Cardiovascular Angiography and Interventions Drug-Eluting Stent Task Force. Cathet Cardiovasc Interv 2007.